Prostate Cancer - Germany Drug Forecasts and Treatment Analysis to 2020

Prostate Cancer - Germany Drug Forecasts and Treatment Analysis to 2020

Summary

GlobalData's pharmaceutical report, “Prostate Cancer - Germany Drug Forecasts and Treatment Analysis to 2020”. The report is an essential source of information and analysis on the German prostate cancer therapeutics market. The report provides comprehensive information on prostate cancer, highlighting the treatment guidelines. It identifies and analyzes the key trends shaping and driving the German prostate cancer therapeutics market, and analyzes the treatment usage patterns. The report also provides insights into the competitive landscape and the emerging players expected to significantly alter the positions of the existing market leaders. The report provides valuable insights into the pipeline products within the global prostate cancer sector. It quantifies the unmet need in the German prostate cancer therapeutics market, highlighting the opportunity for future players.

This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts.

Scope

The scope of the report includes:
- An overview of prostate cancer which includes epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines.
- Annualized German prostate cancer therapeutics market revenue, annual cost of therapy and treatment usage patterns data (for hormone therapy and hormone resistant or refractory therapy) from 2001 to 2009, forecast for 11 years to 2020.
- Insightful review of the key industry drivers, restraints and challenges and predicted impact of key events.
- Competitor assessment including drug launch analysis and drug sales forecasts.
- Product profiles covering efficiency, safety, clinical study details, annual cost, regulatory approvals, LCM (Life Cycle Management) activities and drug sales forecast.
- Analysis of unmet need in the market and target product profiles including opportunity for target products.
- Technology trends analytic framework to assess the strength of the pipeline.
- Pipeline analysis data providing a split across different phases, mechanisms of action being developed and emerging trends. The key classes of mechanism of action include EGFR inhibitors, VEGF inhibitors, tyrosine kinase inhibitor, angiogenesis inhibitors and others.
- An overview of the most promising drugs including clinical study details, efficacy, safety, collaboration agreements, marketing rights and launch analysis.
- Analysis of the current and future market competition in the German Prostate Cancer therapeutics market. Company profiles including business description, financial overview and SWOT analysis. Key future market players covered include Sanofi-aventis, Pfizer, Inc., AstraZeneca PLC, Bristol-Myers Squibb, Medivation, Takeda Pharmaceuticals and Dendreon Corporation.
- Analysis of licensing agreements during 2004-2010 in the prostate cancer therapeutics market. Merger and Acquisition (M&A analysis) which includes M&A deals by size and geography.
- Strategic assessment of the market through market impact analysis, future market scenario and company analysis.
- Direct quotes from key opinion leaders (KOL) or physicians in the prostate cancer therapeutics market in Germany.

Reasons to buy

The report will enhance your decision making capability. It will allow you to:
- Develop business strategies and perform superior market quantification analysis by
- Understanding the trends shaping and driving the German prostate cancer therapeutics market.
- Understanding the treatment preferences of physicians for each disease state and across treatment flow.
- Accessing market sizing forecasts and quantified growth opportunities in the German prostate cancer therapeutics market up to 2020.
- Quantifying the patient population in the German to better design product pricing and launch plans.
- Drive revenues, formulate effective sales and marketing strategies and gain in-depth understanding of the competitive landscape by
- Performing benchmarking analysis and growth opportunities against currently marketed products.
- Identifying market entry points based on safety, efficacy, and pricing parameters.
- Assessing competitiveness of products in the market by understanding the strengths and weaknesses of current competition.
- Develop and design your in-licensing and out-licensing strategies by
- Taking a comprehensive look at the disease pipeline and identifying the most promising paradigm-shifting products.
- Assessing the strength of pipeline based on first-in-class, me-too and generic products and their lifecycle management.
- Track drug sales in the German prostate cancer therapeutics market from 2001 to 2020.
- Identify the emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present the best opportunities for consolidation, investments and strategic partnerships.
- What’s the next big thing in the German prostate cancer therapeutics market landscape? Identify, understand and capitalize.

1 Table of contents 4
1.1 List of Tables 7
1.2 List of Figures 8
2 Disease Overview 10
2.1 Overview 10
2.1.1 TNM (Tumor, Nodes, Metastasis) Staging System 10
2.1.2 Jewett-Whitmore system 11
2.2 Epidemiology 12
2.3 Etiology 12
2.4 Symptoms 12
2.4.1 Localized or Locally Advanced Prostate Cancer 12
2.4.2 Metastatic Prostate Cancer 13
2.5 Diagnosis 13
2.5.1 Digital Rectal Examination 13
2.5.2 Prostate Specific Antigen Test 13
2.5.3 Transrectal Ultrasound 14
2.5.4 Prostate Biopsy 14
2.6 Pathology 15
2.6.1 Grading 15
2.7 Treatment 15
2.7.1 Watchful Waiting 15
2.7.2 Radiation therapy 15
2.7.3 Surgery 16
2.7.4 Hormone therapy 17
2.7.5 Chemotherapy Options 18
2.7.6 Other Treatments Being Studied 19
2.8 Treatment Guidelines 19
3 Market Characterization 20
3.1 Germany 20
3.1.1 Market Size 20
3.1.2 Drivers and Barriers 26
3.1.3 Impact on the Market 28
3.1.4 Forecasts 29
3.1.5 Drug Sales 35
3.1.6 Pricing & Reimbursements 39
4 Competitor Assessment 40
4.1 Strategic Competitor Assessment 40
4.1.1 Overview 40
4.1.2 Benchmarking 40
4.1.3 Current Competitor Assessment 44
4.2 Launch Analysis and Sales Forecasts 45
4.3 Product Profiles 46
4.3.1 Taxotere (docetaxel) 47
4.3.2 Casodex (Bicalutamide) 50
4.3.3 Zoladex (Goserelin) 55
4.3.4 Eligard (leuprolide acetate) 57
4.3.5 Firmagon (degarelix) 62
4.3.6 Novantrone (Mitoxantrone hydrochloride) 64
4.3.7 Emcyt (estramustine) 66
4.3.8 Trelstar (triptorelin) 68
4.3.9 Eulexin 69
4.3.10 Delestrogen 71
4.3.11 Gynodiol 72
4.3.12 Estrace tablet 73
4.3.13 Tace 73
4.3.14 Nilandrone 74
4.3.15 Premarin 75
4.3.16 Sales Forecast for Trelstar, Decapeptyl, Gonapeptyl, Flutamide, Estradiol 76
5 Pipeline Assessment 77
5.1 Overview 77
5.2 Pipeline Analysis by Phase of Development 78
5.3 Pipeline by Mechanism of Action 79
5.4 Strategic Pipeline Assessment 80
5.4.1 Technology Trends Analytical Framework 80
5.5 Trends in Prostate Cancer Pipeline 81
5.5.1 More Clarity on the Origin of Prostate Cancer Will Help in Identifying Novel Targets for Prostate Cancer Drugs 81
5.5.2 Molecules with Novel Mechanism of Action Strengthening Prostate Cancer Pipeline 81
5.5.3 Failure of Key Molecules to Achieve Positive Results in Phase III Development 81
5.6 Partners in Research and Development 82
5.6.1 Licensing Agreements by Phase of Development 82
5.6.2 Licensing Agreements by Geography 85
5.6.3 Licensing Agreements: Technology Licensing Agreements in Prostate Cancer 85
5.7 Most Promising Drugs’ Profiles 86
5.7.1 Provenge (sipuleucel-T) 87
5.7.2 Jevtana (cabazitaxel) 90
5.7.3 Aflibercept (VEGF Trap) 91
5.7.4 Ipilimumab 94
5.7.5 Abiraterone Acetate (CB7630) 96
5.7.6 Zibotentan (ZD4054) 98
5.7.7 Sprycel (dasatinib) 100
5.7.8 MDV3100 102
5.8 Prostate Cancer Pipeline – Pre-clinical Phase 105
5.9 Prostate Cancer Pipeline – Phase I 106
5.10 Prostate Cancer Pipeline – Phase II 108
5.11 Prostate Cancer Pipeline – Phase III 115
5.12 Key Takeaway 116
6 Unmet Need and Target Product Profile 117
6.1 Unmet Need 119
6.1.1 Hormone-independent Metastatic Prostate Cancer Therapy 119
6.1.2 Hormone-dependent Metastatic Prostate Cancer Therapy 120
6.2 Opportunity for Target Product 121
6.3 Target Product Profile 123
6.3.1 Ideal Characteristics 123
6.3.2 Target Product Description 124
6.4 Key Takeaway 124
7 Strategic Assessment 125
7.1 Key Events Impacting the Future Market 125
7.2 Market Impact Analysis 126
7.3 Future Market Scenario 126
7.4 Company Analysis 127
7.4.1 Market Leadership 127
7.4.2 Future Players in the Market 128
7.5 Key Takeaway 128
8 Company Profiles 129
8.1 Sanofi-aventis 129
8.1.1 Business Description 129
8.1.2 Financial Overview 131
8.1.3 SWOT Analysis 131
8.1.4 Oncology Focus 136
8.2 Pfizer Inc. 136
8.2.1 Business Description 136
8.2.2 Financial Overview 137
8.2.3 SWOT Analysis 138
8.2.4 Oncology Focus 144
8.3 AstraZeneca 145
8.3.1 Business Description 145
8.3.2 Financial Overview 147
8.3.3 SWOT Analysis 147
8.3.4 Oncology Focus 151
8.4 Bristol-Myers Squibb 152
8.4.1 Business Description 152
8.4.2 Financial Overview 153
8.4.3 SWOT Analysis 154
8.4.4 Oncology Focus 159
8.5 Medivation 160
8.5.1 Business Description 160
8.5.2 SWOT Analysis 161
8.5.3 Oncology Focus 164
8.6 Takeda Pharmaceuticals 164
8.6.1 Business Description 164
8.6.2 SWOT Analysis 165
8.7 Dendreon Corporation 166
8.7.1 Business Description 166
8.7.2 SWOT Analysis 167
8.8 Johnson and Johnson 170
8.8.1 Business Description 170
8.8.2 SWOT Analysis 171
8.8.3 Oncology Focus 178
8.9 Auron Healthcare GmbH 179
8.9.1 Business Description 179
8.10 Oncogenex Pharmaceuticals, Inc. 179
8.10.1 Business Description 179
8.11 Agennix AG 179
8.11.1 Business Description 179
8.12 GTx, Inc. 180
8.12.1 Business Description 180
8.13 GlaxoSmithKline plc. 180
8.13.1 Business Description 180
8.13.2 Financial Overview 181
8.13.3 SWOT Analysis 181
8.13.4 Oncology Focus 187
9 M&A Analysis 189
9.1 Key Highlights 189
9.2 Key Deals’ Analysis 190
9.2.1 Johnson & Johnson Acquires Cougar Biotechnology 190
9.2.2 Endo Pharmaceuticals Acquires Indevus Pharmaceuticals 190
9.2.3 Tolmar Holding Acquires QLT USA from QLT 191
9.2.4 Biomarin Pharmaceutical to Acquire Lead therapeutics 191
9.2.5 Isis Pharmaceuticals Reacquires Rights to Cancer Drug from Eli Lilly & Co. 191
9.2.6 Quest PharmaTech Acquires Late-stage Immunotherapeutic Antibody Pipeline from Paladin Labs 191
9.2.7 VaxOnco Acquires Rights to Onyvax-P Cell Vaccine From Onyvax 191
9.2.8 GPC Biotech Merges with Agennix 191
9.2.9 Eli Lilly Acquires ImClone 192
9.2.10 BBM Holdings Acquires YM BioSciences 192
9.2.11 Sagent Pharmaceuticals Acquires Injectable Generic Drug Applications of Spectrum Pharmaceuticals 192
9.3 M&A Deals by Geography 193
9.4 M&A Deals by Deal Size 193
10 Expert Opinion 194
10.1 Germany 194
11 Appendix 195
11.1 Market Definitions 195
11.2 Abbreviations 195
11.3 Research Methodology 197
11.3.1 Coverage 197
11.3.2 Secondary Research 198
11.3.3 Forecasting 198
11.3.4 Primary Research 201
11.3.5 Expert Panel validation 201
11.3.6 Contact Us 201
11.3.7 Disclaimer 201
11.3.8 Sources 202